c-Jun N-terminal kinase (JNK) is activated by diverse cell stimuli, including stress, growth factors, and cytokines. Traditionally, activation of JNK by stress treatment is thought to induce cell death. However, our recent data indicate that JNK's ability to sensitize cells to apoptosis may be, in part, cell cycle dependent. Here, we show that the majority of both paclitaxel-and UV-induced apoptosis can be inhibited by the pharmacological JNK inhibitor, SP600125, in MCF-7 cells. However, inhibition of JNK does little to reverse doxorubicin-induced apoptosis in MCF-7 cells or doxorubicin-and UV-mediated death in MDA MB-231 cells. SP treatment causes G2/M arrest of three breast cancer cell lines and results in the endoreduplication (cellular DNA content 44N) of MCF-7 and MDA MB-231 cells. These effects on cell cycle and apoptosis are not significantly altered by the inhibition of p53, indicating that JNK is functioning independently of p53. Lastly, inhibition of JNK using both SP and antisense oligonucleotides targeted to JNK1 and JNK2 reduced proliferation of all three breast cancer cell lines. Taken together, these results suggest that the activation of JNK is important for the induction of apoptosis following stresses that function at different cell cycle phases, and that basal JNK activity is necessary to promote proliferation and maintain diploidy in breast cancer cells.
Introduction
Cancer growth results from uncontrolled cell proliferation, but augmented survival responses in the presence of cellular stress also contribute to tumor progression and drug-or radioresistance. Many types of cellular stress induce c-Jun N-terminal kinase (JNK), a member of the serine/threonine family of protein kinases known as the mitogen-activated protein kinase (MAPK) family. A wide range of biological outcomes have been attributed to JNK, including enhanced proliferation or survival after exposure to stress, but the majority of published evidence supports JNK's role in conveying apoptotic responses when cells are exposed to cytokines, DNA damage, or anticancer therapies. JNK substrates such as ATF-2, c-Jun, Bcl-2, Bcl-XL, p21 Cip1/Waf1 , and p53 have been identified and have provided insight into the ultimate effect(s) of activated JNK within varying cellular contexts. c-Jun is JNK's most-studied substrate, and it alone leads to complex responses. Phosphorylated c-Jun homo-or heterodimerizes with Fos or ATF-2 to form AP-1 complexes that serve as transcription factors to alter gene expression. Thus, AP-1 is a downstream effector of JNK activity, and it regulates genes such as cyclin D1, p53, p21 Cip1/Waf1 , p19 ARF , and p16, which affect cell proliferation and apoptosis (reviewed in Jochum et al., 2001; Shaulian and Karin, 2001; Vogt, 2001) . Isoform-specific functions may also explain some of the varied and indeed contradictory effects attributed to JNK proteins (Gupta et al., 1996; Minden and Karin, 1997) .
Much attention has focused on the opposing roles of JNK in the regulation of both cell death and, under certain conditions, cell survival (Potapova et al., 2000b; Tournier et al., 2000; Hochedlinger et al., 2002) . For example, inflammatory cytokines such as IL-1 and TNF-a and environmental stress such as ionizing radiation activate JNK to cause growth inhibition (Woodgett et al., 1996) . Microtubule-interfering agents such as paclitaxel, vinblastine, and colchicine initiate apoptosis via mechanisms that involve JNK (Osborn and Chambers, 1996; Wang et al., 1998; Mamay et al., 2003) . By using JNK1À/À and JNK2À/À primary fibroblasts, Tournier et al. (2000) have shown that cells are resistant to UV-induced apoptosis due to inefficient cytochrome c release. However, data regarding the phenotypic response of growth factor activated JNK are more controversial and less studied. Some have shown that when JNK is induced by growth factors, such as insulin-like growth factor-1 (IGF-1), it can promote growth of MCF-7 breast cancer cells (Monno et al., 2000) . In contrast, we and others have shown that JNK activation by IGF-I and other treatments leads to decreased IGF-1 and insulin signaling through its ability to phosphorylate insulin receptor substrate-1 on an inhibitory amino acid, Ser 307 . These findings suggest a possible explanation for JNK's inhibitory effect on growth of cells in anchorage-independent growth and insulin resistance (Aguirre et al., 2000 (Aguirre et al., , 2002 Mamay et al., 2003) .
JNK's role in apoptosis may stem from its ability to regulate the function of the tumor suppressor protein p53. In nonstressed cells, JNK associates with p53 and targets it for ubiquitination and degradation (Fuchs et al., 1998a) . Alternatively, when cells are exposed to stress or DNA damage, JNK phosphorylates p53 and changes it to a more stable conformation (Shieh et al., 1997; Fuchs et al., 1998b, c) . As a result, stress-activated p53 leads to increased expression of p21 Cip1/Waf1 , a cyclin/Cdk inhibitor. p21
Cip1/Waf1 expression increases in response to DNA damage, and cyclin B/Cdk1 kinase activity is inhibited that causes G2 arrest (Bates et al., 1998) . Interestingly, both JNK and p38 MAPK (another stress-activated MAPK) can prolong p21
Cip1/Waf1 mediated responses by phosphorylating Ser 130 and enhancing its stability in HD3 human colon carcinoma cells (Kim et al., 2002) . Continuous increases in p21
Cip1/Waf1 levels may eventually result in decreased JNK activity (Shim et al., 1996; Xue et al., 2003) . For reasons not fully understood, some cells endoreduplicate by replicating DNA without undergoing an intervening mitosis, leading to DNA content 44N. Inhibition of Cdk1 and sustained p21
Cip1/Waf1 activity are both required to prevent endoreduplication (Chang et al., 2000) . Together, these data suggest that JNK may alter either the cell cycle or apoptosis in a p53 or p21
Cip1/Waf1 -dependent or -independent manner.
With these targets in mind, we used a pan JNK inhibitor, SP600125 (SP), to suppress JNK activity and to evaluate the effect of JNK inhibition on cell cycle distribution and ultimately the sensitivity of breast cancer cells to apoptosis. Here, we show that inhibition of JNK using both SP and JNK antisense (AS) strategies reduced proliferation of breast cancer cells. We also demonstrate that JNK inhibition has prominent effects on the cell cycle that may then dictate sensitivity of cancer cells to apoptosis following treatment with specific stress-inducing agents. Together, these data suggest that JNK activity may result in the development of a more malignant and chemoresistant phenotype of aneuploid cells.
Materials and methods

Cell culture
MCF-7, MDA MB-231, and 21PT cells were provided by C Kent Osborne (San Antonio, TX, USA), Kathryn Horowitz (Denver, CO, USA), and Heide Ford (Denver, CO, USA), respectively. MCF-7 and MDA MB-231 cell lines were maintained in IMEM with phenol red (Mediatech, Herndon, VA, USA) supplemented with 10% fetal bovine serum (Gemini, Calabasas, CA, USA), antibiotics, glutamine, and insulin. 21PT cells were maintained in DMEM containing high glucose without sodium pyruvate (Mediatech, Herndon, VA, USA). The media were supplemented as described previously (Band et al., 1990) . In each experiment, cells were plated in full media and cultured overnight at 371C and 5% CO 2 . Cells were then harvested as described in figure legends.
Antibodies and reagents
Anti-JNK (sc-571), phospho-c-Jun (Ser 63) (sc-7980-R), cyclin B1 (sc-245), cyclin E (sc-247), and cyclin A (sc-751) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-poly(ADP) ribose polymerase (PARP) (#556494) was purchased from Transduction Labs (San Diego, CA, USA). Anti-p21 (CP74) was obtained from NeoMarkers (Fremont, CA, USA). Anti-a-tubulin was obtained from Sigma (#T5168). Anti-p53 (Clone PAb1801) antibody was purchased from Oncogene (Boston, MA, USA). SP600125, SB203580, and PD98059 were purchased from Calbiochem (San Diego, CA, USA). All protein concentrations from cell extracts were determined using a Bio-Rad D/C protein assay kit (Bio-Rad, Hercules, CA, USA). Paclitaxel and doxorubicin were obtained from Bristol-Myers Squibb, Co. (Princeton, NJ, USA) and Bedford Laboratories (Bedford, OH, USA), respectively.
AS oligonucleotide transfections
AS oligonucleotides were provided by ISIS Pharmaceuticals, Carlsbad, CA, USA. ISIS 15346, 5 0 -CTCTCTGTAGGCC CGCTTGG-3 0 and ISIS 101759, 5 0 -CTTTCCGTTGGACCC CTGGG-3 0 , AS oligonucleotides (termed JNK1 AS and JNK2 AS, respectively) were used to eliminate the expression of respective JNK proteins. ISIS 114845, 5 0 -TACGTCCGGAG GCGTACGCC-3 0 and 101760, 5 0 -GCACATTGCACGTGAA TTAC-3 0 (termed JNK1 Ctrl and JNK2 Ctrl, respectively) were used as control sequence oligonucleotides for JNK1 AS and JNK2 AS. Transfections were carried out as described previously by Potapova et al. (2000b) .
Transfection of siRNA p53
A pSUPER p53 vector that provides stable expression of short-interfering RNAs (siRNAs) was purchased from Oligoengine (Seattle, WA, USA). The pSUPER p53 constructs were described previously (Brummelkamp et al., 2002) . Cells were plated to 70-80% confluency. The next day, MCF-7 cells were transfected with 5 mg of DNA per 1.0 Â 10 6 cells using LipofectAMINE and PLUS reagent (Invitrogen, Carlsbad, CA, USA). Control cells were transfected with empty vector.
JNK activity assays
As a positive control for JNK activation, cells were plated and serum starved as described previously (Mamay et al., 2003) , and then exposed to either IGF-I and/or chemotherapy as indicated in figure legends. UV irradiation was performed by exposing cells to UVC (50 J/m 2 ) in a Spectrolinkert XL-1000 UV Crosslinker. Tissue culture dishes were washed twice with ice-cold phosphate-buffered saline (PBS). Cells were harvested and in vitro kinase assays were performed as described previously (Hibi et al., 1993) using cell lysate volumes corresponding to 400 mg of total protein. The products were then resolved by 10% SDS-PAGE. The gel was dried and subjected to radiography. Phosphorylated c-Jun 1À79 product incorporating 32 P was quantified by PhosphorImager analysis.
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Cyclin kinase activity assays
A total of 1.5 Â 10 6 cells were lysed in buffer containing 50 mM HEPES-KOH (pH 7.4), 150 mM NaCl, 1 mM of each EDTA, NaF, and DTT, 2.5 mM EGTA, 0.1% Tween-20, 10% glycerol, 10 mM b-glycerophosphate, 0.1 mM Na 3 VO 4, 0.2 mM phenylmethylsulfonyl, and 10 mg/ml of aprotinin and leupeptin. Soluble protein (150 mg) was then immunoprecipitated using 1 mg of anti-cyclin A or anti-cyclin B antibodies along with 40 ml of rProtein G Agarose beads (Invitrogen, Carlsbad, CA, USA) overnight at 41C. Beads were then washed three times with lysis buffer and twice with kinase buffer (50 mM HEPES-KOH (pH 7.4), 10 mM MgCl 2 , b-glycerophosphate, 1 mM DTT, 2.5 mM EGTA, 0.1 mM Na 3 VO 4 , and 1 mM NaF). The kinase assay was carried out by combining the washed beads with 40 ml of kinase buffer plus 10 mCi of [gATP-32 P], 15 mM ATP, and 0.5 mg Histone H1 (Cat. #223-549, Boehringer Mannheim). The reaction was carried out for 20 min at 301C and was stopped using 4 Â Laemmli sample buffer (Motwani et al., 2000) . Products were resolved using 10% SDS-PAGE and autoradiography as described above.
Flow cytometry
Cells (1 Â 10 6 ) were fixed in cold methanol and stained with propidium iodide (PI). Cells were analysed using a Becton Dickenson FacsCalibur and Cellquest software (San Jose). Doublets were excluded from the analysis using the peak vs integral gating method. All studies were performed using the University of Colorado Cancer Center Flow Cytometry Core (supported by NIH Grant 5 P30 CA 46934-15).
MTT assay
MCF-7 cells were transfected as described above with AS oligonucleotides to JNK1 or JNK2 (JNK1 and JNK2 AS) or oligonucleotide controls (Ctrl1 and Ctrl2 AS). At 1 day after transfection, 2 Â 10 4 cells were plated into each well of a 24-well plate. Each day following for 4 days, 80 ml of MTT solution (5 mg/ml in PBS) was added to each well. Cells were incubated at 371C for 4 h. MTT crystals were then solubilized in 800 ml of DMSO þ 2.5% media. Since responses were linear with time, differences in treatment were compared using a twoway analysis of variance (ANOVA). In separate experiments, 2 Â 10 4 MDA MB-231 or 21PT cells were plated in each well of a 96-well plate. After 1 day, either 25 mM SP600125 or DMSO alone was added to fresh media then used to culture cells. SP treatment was repeated every 48 h. Each day following for 4 days, 20 ml of MTT solution was added to each well. Cells were incubated at 371C for 4 h. At each indicated time point, MTT crystals in each well were solubilized in 200 ml of DMSO þ 2.5% media. Absorbance was read at 550 nm.
Results
SP600125 and AS oligonucleotides inhibit JNK kinase activity and protein levels, respectively, in breast cancer cells
To inhibit JNK and further assess JNK-mediated phenotypes in breast cancer cells, we used both a new pharmacological inhibitor of JNK (SP600125) and JNK AS strategies. First, we optimized SP600125 (SP) treatment conditions to inhibit JNK activation. Cells were pretreated for 10 min using increasing concentrations of SP to inhibit UV activation of JNK, allowing us to demonstrate a dose-response relationship where the effective inhibitory concentration was 10-25 mM ( Figure 1a ). We then determined the duration of SP inhibition of JNK by incubating cells in SP-containing media for indicated times and then stimulating JNK activity using phorbol 12-myristate 13-acetate (PMA), a known activator of JNK (Chen et al., 1996) , for 30 min prior to harvesting cells (Figure 1b) . From these data, we were able to conclude that SP has sustained stability and inhibitory function out to 48 h when used in cell culture conditions.
Since SP is a non-isoform-specific inhibitor of JNK, we also tested JNK AS strategies to inhibit efficiently both JNK expression and activity in an isoform-specific manner. Similar to results of other investigators (Potapova et al., 2000a) , we observed significant inhibition of both JNK1 p46 and JNK2 p54 expression; however, these oligonucleotides did not inhibit JNK1 p54 and JNK2 p46 isoform expression (Figure 2a ). Despite somewhat incomplete suppression of JNK protein expression, JNK kinase assays show that when both isoforms are targeted, JNK activity is inhibited in response to both UV irradiation and IGF-I treatment following AS treatment (Figure 2b ).
SP600125 inhibits stress-induced apoptosis in breast cancer cell lines
Our previous work using overexpression of a dominantnegative mutant JNK indicated that the inhibition of JNK activity protects MCF-7 cells from paclitaxelinduced apoptosis (Mamay et al., 2003) . We wanted to confirm these observations using the SP compound and to expand our studies using other breast cancer cell lines and stress treatments that may or may not induce JNK activity. For example, we have previously shown that doxorubicin treatment does not significantly enhance JNK activity (o2-fold), but all other treatments used induce JNK to varying degrees in MCF-7 cells (UV44paclitaxel4doxorubicin) (Mamay et al., . Additionally, we used anisomycin to induce JNK activity in breast cancer cells (Aguirre et al., 2000) . Thus, to test if SP only inhibits apoptosis by agents that activate JNK, we treated MCF-7 and MDA MB-231 human breast cancer cells with UV, anisomycin, paclitaxel, or doxorubicin alone or each of these agents in combination with SP. At the indicated times, cells were analysed for apoptosis by Western blot analysis of caspase-dependent PARP cleavage to an 85 kDa fragment. In MCF-7 cells, SP cotreatment inhibited paclitaxel, UV, and anisomycin-induced PARP cleavage. In contrast, SP had little effect on doxorubicininduced PARP cleavage (Figure 3a ). To confirm these results, we repeated these assays using the MDA MB-231 cell line. At the concentrations used, paclitaxel treatment induced less apoptosis in MDA MB-231 cells, whereas doxorubicin-and UV treatment-induced apoptosis was more readily observed. SP600125 cotreatment of MDA MB-231 with these treatments was less efficient at reversing treatment-induced apoptosis. In general, the protective effect of SP600125 was 50% at best ( Figure 3b ). Considering that these protective effects were observed with doxorubicin as well as the other treatments that induce JNK to an even greater extent, we then decided to determine if these protective effects may result from SP-induced cell cycle arrest.
Inhibition of JNK causes G2/M arrest and endoreduplication in breast cancer cells independent of p53 function
Given that most chemotherapy drugs target proliferating cells to induce cell death and that SP protected from apoptosis somewhat independently of the treatment's ability to induce JNK activity, we reasoned that these varied responses might result from a cell cycle-dependent effect of each treatment. Further, we observed more protection with SP treatment of the MCF-7 cell line compared to the MDA MB-231 cell line. One notable difference in these cell lines is their p53 status: MCF-7 cell express wild-type p53 and MDA MB-231 cells express mutant p53. Given that JNK mediates both p53 and p21 Cip1/Waf1 stability and function, we thought that JNK's effect on the cell cycle might be p53 dependent. Thus, to first determine if the SP treatment would alter the cell cycle, we treated MCF-7, MDA MB-231, and 21PT breast cancer cells with SP, and then subjected the cells to FACS analysis using PI staining to measure DNA content. Figure 4a shows cell cycle distributions for the three cell lines when growing asynchronously in subconfluent conditions, with only DMSO (vehicle) added. In contrast, SP treatment for 48 h induced a significant fraction MDA MB-231 cells to G2/M arrest, while another population of cells underwent apoptosis, as seen by a sub-G1 peak. Another small fraction of MDA MB-231 cells underwent endoreduplication (DNA (Figure 4b ). These data support the theory that basal JNK serves an important role during G2/M transit.
Given these results and the previous observations by others showing that JNK activity is induced by genotoxic stress in a similar fashion to wild-type p53, we wanted to differentiate if JNK may be acting via p53 or independently. Importantly, each of the three cell lines used in Figures 4a and b have a different endogenous p53 status: MCF-7 cells express wild-type p53, MDA MB-231 cells express mutant p53, and 21PT cells express p53 truncated at the N-terminus (Courtois et al., 2002) . Since each cell line displayed altered cell cycle distributions with SP treatment, we wanted to determine if p53 function correlated with these cell cycle changes. Thus, we decided to inhibit the effects of p53 in wild-type p53-expressing MCF-7 cells. We used g irradiation to activate p53 function in MCF-7 cells and to induce G2/M arrest (Figure 4c ). To ascertain p53-dependent and -independent consequences of JNK inhibition, p53 activity was inhibited using siRNA with the p53SUPER construct (Brummelkamp et al., 2002) . As seen in Figure 4c , MCF-7 cells that were transfected with p53SUPER, but not irradiated, experienced only a small decrease in the fraction of cells in G2/M. However, when MCF-7 cells were exposed to g irradiation, siRNA inhibition of p53 reduced the fraction of G2/M arrested cells (Figure 4c) , consistent with the loss of p53 function. When comparing histograms in Figure 4d to those in Figure 4c , we also observed a slightly higher proportion of cells arresting in (SB) or 10 mM PD98059 (PD), and analysed as above. (f) MCF-7 cells were transfected with p53 siRNA for 48 h and then exposed to g irradiation (3 Gy) for 24 h. p53 and p21 levels were determined by Western blotting as described in Materials and methods. (g) MCF-7 cells were exposed to SP 10-25 mM for 20 min and then lysed. Phosphorylated substrate was measured as described in Materials and methods. Data graphed are from two independent experiments. (h) MCF-7 cells were lysed at indicated time points. Total protein lysate (60 mg ) was separated by SDS-PAGE, and then Western blotted with antibodies to the indicated proteins G1 and more apoptotic cells in sub-G1 after g irradiation and SP treatment. Overall, however, most cell cycle changes observed with SP treatment of MCF-7 cells remain unchanged during genotoxic stress, indicating that inhibition of basal JNK (in the absence of p53) enhances apoptosis (sub-G1 cells) and G2/M arrest. Irradiation and siRNA of p53 also did not alter SP-induced endoreduplication in MCF-7 cells (Figure 4d) .
Since JNK and p38 MAPK may both phosphorylate p21
Cip1/Waf1 to lead to similar effects on the cell cycle (Haq et al., 2002; Kim et al., 2002) , we wanted to rule out the possibility that other members of the MAP kinase family might convey the same cell cycle responses. Thus, we tested if a p38-specific inhibitor, SB203580, would result in similar effects on the cell cycle. We also tested if inhibition of ERK, using PD98059, could lead to these effects. Neither inhibitor led to significant changes in the cell cycle distribution of MCF-7 cells after 48 h (Figure 4e ) or 72 h of treatment (data not shown), indicating that the G2/M arrest or endoreduplication observed in these cells is most likely a result of inhibition of basal JNK activity. Lastly, we assessed the efficiency of our p53 siRNA construct. To this end, MCF-7 cells were transfected with pSUPER p53 and then harvested 48 h later. MCF-7 cells were also treated with g irradiation, then lysed 24 h later as a positive control for p53 induction. Further, we measured p21
Cip1/Waf1 protein levels to verify that inhibition using siRNA resulted in a decrease in downstream effectors of p53. Figure 4f confirms that p53 protein and subsequent p21
Cip1/Waf1 levels were decreased following p53 siRNA transfection of MCF-7 cells.
As mentioned above, we initially treated cells with 25 mM of SP; however, during the course of our experiments, other investigators reported that SP may have some nonspecific effects at 410 mM concentrations. According to Bain et al. (2003) , SP treatment at concentrations 410 mM can inhibit cyclin A/Cdk kinase activity. Since we were interested in JNK's effects on cell cycle and apoptosis, we assessed the ability of SP to inhibit directly cyclin/Cdk kinases involved in G2/M transit, namely cyclin A-and B-associated kinase activities. Figure 4g demonstrates that SP does not have a significant effect on the kinase activity of cyclin A/Cdk or B/Cdk complexes, further supporting that SP is working through JNK inhibition and not by direct inhibition of cyclin/Cdk complexes important in G2/M transit. To further these observations, cell cycle analyses using SP at 10 mM confirmed that a lower concentration had comparable effects; SP at 10 mM has an equally strong but more delayed effect (data not shown).
Finally, as a more elaborate indicator of the kinetics of SP-induced cell cycle changes, we performed Western blot analyses of the several cell cycle regulatory proteins (Figure 4h ). Asynchronous MCF-7 cells were treated with either 10 or 25 mM SP for 24-72 h and then harvested. As a positive control for both cyclin and p21
Cip1/Waf1 changes during G2/M arrest, cells were treated with g irradiation (3 Gy), then cultured for 48 h. As reported by others (Flatt et al., 2000) , g treatment leads to cyclin B degradation and an increase in p21
Cip1/Waf1 after 48 h, consistent with G2/M arrested cells (Figure 4h, lane 2) . SP treatment initially increased both cyclin E and A; however, both levels eventually decreased indicating transit from S phase to G2/M. In contrast to g irradiation, cyclin B levels increased and remained high with SP treatment, while p21 Cip1/Waf1 initially increased but then decreased to control levels after 72 h of exposure. These analyses suggest that the initial increases in p21
Cip1/Waf1 and cyclin B are arresting cells in G2/M. The reduction of p21
Cip1/Waf1 at later time points may explain why some cells can traverse G2 without entering mitosis, resulting in endoreduplication.
Inhibition of JNK reduces proliferation of breast cancer cells
We recently reported that overexpression of JNK inhibits anchorage-independent growth in MCF-7 cells (Mamay et al., 2003) . Given this response and our results showing cell cycle arrest in three breast cancer cell lines with the inhibition of basal JNK, we tested if (Figure 5b ). These assays indicated that the reduced cell cycle progression due to JNK inhibition is not a transient effect; rather, it results either in sustained arrest or ultimately cell death. Using these assays, we were unable to assess the fate of the endoreduplicating population of cells observed by FACS analysis. This population of cells is of particular interest in that we are uncertain if they ultimately undergo mitotic crises and die, or persist as aneuploid cells with increased resistance to chemotherapeutic agents.
Discussion
The opposing roles of the JNK signaling pathway have been more intensely studied over the past few years.
Extra focus has been placed on the apoptotic role of JNK following cellular stress; however, some reports have suggested that JNK is also important in survival and proliferation (Potapova et al., 2000a, b) . Until recently, a large number of the studies involving JNK and its functionality have used transient systems where JNK is overexpressed in either a wild-type or mutant form. The use of knockout JNK1 and JNK2 mice, AS technology, and a new commercially available inhibitor of JNK, SP600125 (Bennett et al., 2001) , have recently led to an increased understanding of the basal and stress-activated role(s) of JNK in various cellular contexts. In this paper, we demonstrate some important phenotypic effects of inhibition of basal and stressactivated JNK on breast cancer cells.
First, we show that inhibition of JNK with both SP600125-and JNK-specific AS oligonucleotides significantly reduces JNK's activity and expression levels in MCF-7 cells. SP is a reversible, competitive ATP inhibitor of JNK that targets JNK1, JNK2, and JNK3 with 420-fold selectivity over a wide range of kinases and enzymes, including the other MAP kinases, p38, and ERK (Bennett et al., 2001) . Here, we demonstrate that SP is a very strong inhibitor of c-Jun phosphorylation, and its activity is sustained in culture. Additionally, we show that the SP inhibitor can reduce JNK phosphorylation of c-Jun following diverse stimuli (UV, PMA). We also used a different approach to JNK inhibition using AS oligonucleotides to determine selectively isoform-specific effects of JNK. Use of the AS strategy has allowed us to corroborate many JNKspecific effects that we observed with the SP compound. Unfortunately, AS targeting of JNK was less amenable to use in assays that require several days. Likely reasons include: (1) the AS oligonucleotides that we used do not inhibit all JNK isoforms; (2) the wide range of half-lives for the different JNK isoforms (JNK1 t 1=2 ¼ 14h versus JNK2 t 1=2 ¼ 24h) makes it difficult to compare directly the isoform-specific effects in the assays we used here (Potapova et al., 2000a); and/or (3) there may be instances where JNK protein is required but not its activity. The latter example would indicate its importance as a potential scaffolding protein.
Our previous work showed that overexpression of wild-type JNK in MCF-7 cells enhanced stress-induced apoptosis (Mamay et al., 2003) ; thus, we wanted to determine if inhibition of JNK would decrease stressinduced apoptosis. Recent reports have linked JNK to apoptotic responses in multiple ways. For example, fibroblasts lacking both JNK1 and JNK2 were recently shown to be resistant to apoptosis induced by UV irradiation due to incomplete cytochrome c release (Tournier et al., 2000) . Our data confirm that JNK activation is required, at least in part, for UV-induced apoptosis. In addition, JNK activity is required at least in part for apoptosis that results from treatment with other stress activators (i.e. paclitaxel and anisomycin). Attempts to confirm our data using specific AS strategies to eliminate JNK protein proved to be inconclusive. These discrepancies may also indicate that the presence of JNK protein may induce effects through the degradation of its substrates, whereas activation of JNK in turn activates its substrates and often stabilizes them (Fuchs et al., 1998c) . Examples of the ability of JNK to alter the stability of its substrates include p53 and p21
Cip1/Waf1 . This indicates that JNK may have functions unrelated to its kinase activity. Most importantly, the use of SP60015 inhibits the kinase activity of all 10 JNK isoforms (Bennett et al., 2001) , whereas our AS approach only targets two isoforms, JNK1 (46 kDa) and JNK2 (54 kDa). Differences in outcomes observed with SP treatment compared to JNK AS strategies suggest that other JNK isoforms may either have diverse biological effects or compensate for the loss of other JNK proteins. This is a likely explanation when considering the findings of Tournier et al. (2000) who used fibroblasts that were null for the JNK1 and JNK2 genes; thus, there was no potential for other splice variants of JNK. Thus, despite the controversial role for JNK in apoptosis, our data still provide a clear role for JNK in increasing chemosensitivity of cancer cells via its importance in cellular proliferation and cell cycle regulation.
Our data clearly show that the ability of JNK to regulate apoptosis does not depend on p53 function, since the effect of SP on chemotherapy-induced apoptosis was more selective for paclitaxel rather than doxorubicin in MCF-7 cells. Although somewhat disputed, it is generally thought that the ability of paclitaxel to induce apoptosis in cancer cells is p53 independent (Bacus et al., 2001) , whereas the efficacy of doxorubicin on cancer cells is in large part p53 dependent. Further, SP provided some protection from doxorubicin-mediated apoptosis in MDA MB-231 cells, which express mutant p53. Together, our data support that JNK-mediated apoptosis is likely cell cycle dependent but independent of p53. Further, JNK's ability to induce apoptosis appears to be unique to stress treatments that induce mitotic arrest, including the microtubulin-interfering agents. Thus, cells arrested in G2, due to JNK inhibition, may be unable to enter M phase where these agents are most active.
Limited work has been published regarding the potential role of JNK in the cell cycle. Activated JNK associates with centromeres during S phase and again in anaphase (MacCorke-Chosnek et al., 2001) . A recent study by Potapova and co-workers reported that JNK1 and JNK2 AS treatment inhibited T98G glioblastoma cell proliferation in the absence of stress. Both JNK1 and JNK2 AS treatment resulted in cell accumulation in S phase. JNK2 AS treatment alone had prominent effects on S phase arrest associated with a p53-independent induction of p21
Cip1/Waf1 and subsequent decreases in both Cdk1 and Cdk2 kinase activity. Moreover, JNK2 AS also resulted in the presence of cells containing 42N DNA content, while other cells detached from the tissue culture plate, indicating apoptosis. These results suggest that inhibition of JNK2 can result in at least three distinct outcomes in the same cell population: cell cycle arrest, endoreduplication, and/or apoptosis. Although we were unable to observe the responses using JNK AS approaches, preliminary data using MKK4 and MKK7 AS oligonucleotides, kinases upstream of JNK, show some S phase increases (data not shown).
Our results using SP treatment corroborate Potapova's findings. We show that JNK activity is required for normal progression of breast cancer cells through the cell cycle. When treated with SP, MCF-7, and MDA MB-231 cells arrest in G2/M and undergo endoreduplication. The G2 arrest induced by SP treatment may be due to the inability of some cells to sustain p21
Cip1/Waf1 levels in the absence of JNK activity. When p21 Cip1/Waf1 expression is increased in response to DNA damage and p53 action, cyclin B/Cdk1 kinase activity is inhibited causing G2 arrest (Bates et al., 1998) . Patel et al. (1998) have shown that the activity of JNK is important for the dissociation of p21
Cip1/Waf1 and JNK and entry of cells into S phase. Thus, inhibition of JNK might prevent JNK from dissociating from p21
Cip1/Waf1 and inhibiting cyclin B/Cdk1 activity. In addition, loss of p21 Cip1/Waf1 levels may then result in endoreduplication (Kim et al., 2002) . Here, we showed that an increase in p21
Cip1/Waf1 levels coincided with the onset of G2/M arrest, but that endoreduplication may have developed due to an inability to sustain high p21
Cip1/Waf1 levels. Chang et al. (2000) recently demonstrated the importance of p21
Cip1/Waf1 in preventing endoreduplication by using a p21
Cip1/Waf1 -inducible expression system in p21 Cip1/Waf1 (À/À) cells. Induction of p21
Cip1/Waf1 expression decreased DNA replication, mitosis, and expression of proteins involved in the execution or control of mitosis, namely Cdk1 (cdc2). When p21 Cip1/Waf1 expression was later turned off, abnormal mitoses resulted, probably due to insufficient recovery of mitotic-and replication-associated proteins (Chang et al., 2000) . These data show that the inhibition of Cdk1 and sustained p21 Cip1/Waf1 activities are both required to prevent endoreduplication.
Given our findings here, p21 Cip1/Waf1 may be an important target for JNK's cell cycle effects in our model. Similarly, in T lymphocytes, JNK is rapidly activated following G1/S phase arrest and preceding S phase progression, and its activation appears to be dependent on its association with p21 Cip1/Waf1 (Patel et al., 1998) . In considering these findings, one would predict that JNK activity (instead of inhibition of JNK activity) may lead to G2/M arrest, but we and others have shown similar responses by inhibiting basal JNK (Potapova et al., 2000a) . In addition, Gadd45a (growth arrest and DNA damage inducible gene) has effects similar to p21 Cip1/Waf1 in that both are targets of JNK and p53 activity, and both can ultimately lead to G 2 /M arrest (Hildesheim et al., 2002; Kim et al., 2002) . JNK induces Gadd45a expression, which then inhibits cyclin B/Cdk1 kinase activity (Wang et al., 1999; Jin et al., 2000; Yang et al., 2000) . In Gadd45a-null mice treated with UV irradiation, p38 and JNK activities are decreased resulting in inadequate p53 activation and loss of G1 and G2 cell cycle checkpoints (Hildesheim et al., 2002) . Together, these results show that Gadd45a and p21
Cip1/Waf1 have similar and often parallel effects in the cell cycle. Thus, it will be interesting to determine how JNK might regulate each of these proteins differentially to convey its effects on the cell cycle.
In summary, our work demonstrates that basal JNK is required for continued cell proliferation of breast cancer cells and that JNK functions during G2/M transit in a p53-independent fashion to prevent endoreduplication. Further, the cell cycle functions of JNK provide important directions for future study regarding how JNK conveys its proapoptotic activity. JNK may be differentially regulated in normal vs cancer cells and if so, then JNK may prove to be a promising target for cancer treatment.
